Depression Treatment Market by Products, Disease, Distribution Channel - Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Depression Treatment market was valued at USD 11.1 billion in 2021 and it is expected to hit around USD 17.8 billion by 2030 with a CAGR of 6.9% during the forecast period 2022 to 2030.

According to a recent study, drugs are the leading segment in terms of products and accounted forover 99.8% of demand share in 2021. The depression treatment market holds approximately 7.8% of the global behavioural health market worth US$ 128.29 Bn in 2021.

According to World Health Organization (WHO), prevalence of mental health disorders and conditions is increasing across the globe. There has been a 13% increase in mental health conditions and other depressive disorders in the last decade.

According to the U.S. Department of Health and Human Services (HHS), in 2020, among adolescents between ages 12 and 17, 17.0% (about 4.1 million population) had major depressive episode (MDE), and 12% (about 2.9 million people) had MDE with severe impairment.

Several factors such as demographic changes, environmental conditions, and increasing mental stress are resulting in rising mental health disorders. This is improving the growth in depression treatment market.

According to Nova one advisor, companies operating in the global depression treatment market are actively seeking to strengthen their position through mergers with established as well as emerging market players. For instance, in November 2020, Mylan completed a merger with Upjohn to form Viatris Company.

Report Scope of the Depression Treatment Market

Sales Analysis Of Depression Treatment From 2012 To 2021 Vs Market Outlook For 2022 To 2030

As per FMI, the overall sales of depression treatment expanded at a CAGR of 3.9% from 2012 to 2021 owing to the increase in the prevalence of depression and anxiety disorders. Growth is also contributed to the growing need for antidepressants and therapies to treat mental conditions during the forecast period 2022-2030

Depression treatments during a medical visit is time consuming, and it is essential that people get treatment on time for depression. If conflicting demands continue to obstruct depression treatment, initiatives must ensure that patients with chronic physical difficulties receive high-quality mental healthcare in primary care.

According to a survey by the American Psychological Association (APA) in 2021, due to the pandemic, mental health issues are continuing to surge. Also, there has been a significant increase in demand for treatments for anxiety and depression compared to the last year.

Further, several new developments in antidepressants in the treatment of depression are being carried out in different drug classes, such as selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), antipsychotics, and others.

Recently, there has been a major shift in the market for depression disorders and other mental health disorder treatments. Numerous researchers and sponsors are developing novel drugs for the treatment of depression and getting approvals for them in different regions.

For instance, In September 2018, Alembic Pharmaceuticals received US FDA approval for its Desvenlafaxine ER capsules, 25 mg. A slew of these products launches and approvals of novel drugs and therapies in recent years is affecting the depression treatment market positively.

On the back of these aforementioned factors, the sales in the depression treatment market are expected to increase at a CAGR of 5.8% from 2022 to 2030 globally.

Some of the prominent players in the Depression Treatment Market include:

• Viatris (Mylan Pharmaceuticals Inc.)
• Sunovian Pharmaceuticals
• AbbVie Inc. (Allergan, Inc.)
• Jubilant Generics Limited
• Sanis Health Inc.
• Abbott Laboratories
• Aurobindo Pharma
• Torrent Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharmaceuticals
• (Apotex Holdings, Inc.) Apotex Corporation
• Alembic Pharmaceuticals Limited
• Pfizer Inc.
• Cardinal Health
• Hikma Pharmaceuticals
• Zydus Lifesciences (Cadila)
• Cipla Ltd
• Dr. Reddy's Laboratories
• Merck & Co.
• Eli Lily & Co
• GlaxoSmithKline
• Takeda Pharmaceuticals
• BrainsWay Ltd.
• Nexstim Plc
• Magstim Ltd.
• Neuronetics, Inc.
• Salience TMS Neuro Solutions
• MagVenture
• MAG & More GmbH
• Neurosoft, Ltd.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Depression Treatment market

By Products:

• Drugs
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Citalopram
• Escitalopram
• Fluoxetine
• Fluvoxamine
• Paroxetine
• Sertraline
• Selective Norepinephrine Reuptake Inhibitors (SNRIs)
• Desvenlafaxine succinate
• Duloxetine
• Levomilnacipran
• Venlafaxine
• Bupropion
• Mirtazapine
• Monoamine oxidase inhibitors (MAOIs)
• Phenelzine
• Tranylcypromine
• Antipsychotics
• Lithium carbonate
• Aripiprazole
• Brexipiprazole
• Quetiapine
• Trazodone
• Others
• TMS Devices
• rTMS Devices
• dTMS Devices

By Disease:

• Major Depression
• Persistent Depressive Disorder
• Bipolar Disorder
• Seasonal Affective Disorder (SAD)
• Postpartum Depression
• Premenstrual Dysphoric Disorder (PDD)
• Situational Depression
• Atypical Depression
• Treatment-Resistant Depression

By Distribution Channel:

• Hospitals
• Retail Pharmacies
• Drug Stores
• e-commerce
• Specialty Clinics

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Depression Treatment industry analysis from 2022 to 2030 to identify the prevailing Depression Treatment industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Depression Treatment industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Depression Treatment industry trends, key players, market segments, application areas, and market growth strategies.